A post-hoc analysis of the PACIFIC trial found that baseline proton pump inhibitor (PPI) use was associated with significantly shorter PFS and OS in patients on durvalumab for unresectable stage III NSCLC. Separately, new real-world data from the TRACER HERTras study showed an ORR of 54.8% and mPFS of 7.2 months with trastuzumab deruxtecan (T-DXd) in 168 patients with HER2-mutant NSCLC. In other news, final results from CheckMate 73L showed nivolumab-based strategies failed to improve outcomes versus the standard of care in stage III NSCLC.
“Post-hoc analysis of the PACIFIC trial: baseline PPI use was associated with significantly shorter PFS and OS in patients receiving durvalumab after chemoradiotherapy for unresectable stage III NSCLC.”
— @Dr_ElvinaA · PACIFIC Post-Hoc Analysis · View post ↗📌 Amplified by @KolPulseAI
“In a ph3 trial, nivolumab + CCRT followed by nivolumab ± ipilimumab failed to improve PFS or OS vs standard CCRT followed by durvalumab in unresectable stage III NSCLC.”
— @diegoadiazg · CheckMate 73L Results · View post ↗📌 Amplified by @KolPulseAI
“TRACER HERTras study just out in @JTOonline , the biggest RWD cohort on T-DXd in #HER2mut #NSCLC:”
— @g_mountzios · T-DXd Real-World Data · View post ↗📌 Amplified by @KolPulseAI
“📖 Accompanying editorial: "Not Always ICANS: Interpreting Neurotoxicity With Tarlatamab in SCLC"”
— @M_Torasawa · Tarlatamab Neurotoxicity · View post ↗📌 Amplified by @KolPulseAI
The US FDA has approved sacituzumab govitecan for first-line metastatic triple-negative breast cancer (TNBC), for use with or without pembrolizumab. This approval is based on findings from the ASCENT-03 and ASCENT-04 trials.
“Sacituzumab Govitecan ± Pembro is now @US_FDA ✅ in 1L metastatic TNBC off #ASCENT03/04!”
— @OncBrothers · FDA approval in 1L mTNBC · View post ↗📌 Amplified by @KolPulseAI
“Here’s the most recent #BreastCancer Research Digest-a summary of last week’s publications from select high-impact journals (June 26th - July 2nd, 2026).”
— @DFCI_BreastOnc · Breast Cancer Research Digest · View post ↗📌 Amplified by @KolPulseAI
Results from ESMO GI 2026 are generating discussion. The KRYSTAL-10 trial missed its primary endpoint, as adagrasib plus cetuximab missed its primary endpoint in second-line KRAS G12C mCRC. In pancreatic cancer, the GLEAM trial of zolbetixumab plus GnP was also negative. In contrast, early data for zoldonrasib plus chemotherapy in first-line KRAS G12D PDAC showed promising activity, with ORRs of 61-82%.
“KRYSTAL-10: Adagrasib + cetuximab misses its primary endpoint in 2L KRAS G12C mCRC.”
— @GIMedOnc · KRYSTAL-10 mCRC data · View post ↗📌 Amplified by @KolPulseAI
“Zoldonrasib + ChT showed promising early activity in 1L PDAC:”
— @DraMartinezLago · Zoldonrasib in PDAC · View post ↗📌 Amplified by @KolPulseAI
Results from the ARTO trial show that adding SBRT to abiraterone and ADT improved overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC). Other conversations in prostate cancer include new ESTRO consensus recommendations for focal boost radiotherapy and the identification of a rare, inherited CDK12 mutation in men with aggressive disease.
“New "1 in 1000" prostate cancer discovered: of 4534 men with aggressive prostate cancer, 5 carried an inherited CDK12 mutation.”
— @DrMHofman · Inherited CDK12 mutation · View post ↗
“ESTRO consensus recommendations on how to focal boost the intraprostatic tumour in prostate cancer.”
— @jryckman3 · Prostate cancer radiotherapy · View post ↗📌 Amplified by @KolPulseAI
“Adding SBRT to abiraterone + ADT significantly improved overall survival (HR 0.55).”
— @GiulioFrancoli1 · ARTO trial · View post ↗📌 Amplified by @KolPulseAI
“Radiation improves survival in prostate cancer when the metastatic burden is low. STAMPEDE showed it in hormone-sensitive disease, radiating the primary. ARTO now carries that logic into castration-resistant disease, radiating the metastases.”
— @katy_beckermann · Radiotherapy in prostate cancer · View post ↗In relapsed myeloma, results from the MajesTEC-9 trial showed teclistamab outperforming both PVd and Kd. Attention is also on new sub-analyses from the CASSIOPEIA trial, which include a transcriptomic profile that identified new risk categories and refined the predictive value of MRD for certain patient groups.
“Transcriptomic profiling of CASSIOPEIA pts identified 5 subtypes & 3 risk categories w/ 72-month PFS rates of 70%/51%/27% & refined value of MRD by identifying high-risk pts in whom MRD was insufficient to predict outcome:”
— @Myeloma_Doc · CASSIOPEIA sub-analysis · View post ↗📌 Amplified by @KolPulseAI
“Results from CASSIOPEIA trial suggest pts w/ cyclin D1 overexpression & t(11;14) exhibit slower response rates after induction & high-dose therapy in setting of triplet or quads but long-term prognosis remains favorable:”
— @Myeloma_Doc · CASSIOPEIA t(11;14) sub-analysis · View post ↗
“MajesTEC-9 Results : Teclistamab Outperforms PVd & Kd in Relapsed #Myeloma:”
— @MyelomaTeacher · MajesTEC-9 trial · View post ↗📌 Amplified by @KolPulseAI
“Our new USMIRC analysis evaluated 845 multiple myeloma clinical trials registered on https://t.co/M3vaaOWo7A over the past 20 years”
— @Abdallah81MD · Clinical trial landscape analysis · View post ↗In DLBCL, a new post-hoc analysis suggests the benefit of pola-R-CHP is pronounced in patients with low M1-like macrophage infiltration; the recent publication of the frontMIND trial is also drawing interest. For AML, conversations include the OPTI-AML trial design comparing venetoclax durations and the utility of the PRISM-AML model for allogeneic transplant decisions.
“low M1-like macrophage infiltration = worse PFS/OS with R/GCHOP, but NOT prognostic with pola-R-CHP”
— @majorajay · pola-R-CHP in DLBCL · View post ↗
“Indolent Mantle Cell lymphoma usually presents”
— @UyanikMehmetS · Indolent Mantle Cell Lymphoma · View post ↗
“Can PRISM-AML help decide who should undergo allogeneic transplant after azacitidine + venetoclax? The answer is yes… but with caution.”
— @HenrychihangFu1 · PRISM-AML for transplant decisions · View post ↗
“RCT of tafa-len-R-CHOP vs R-CHOP for 1L DLBCL. Is it enough to change practice?”
— @Eddie_Cliff · frontMIND trial · View post ↗📌 Amplified by @KolPulseAI